Sales below 12m trailing average

A dangerous cocktail emerging

Anti-vaxxer fanatics threaten 40% of SOBI EBIT

Building Norway to rebound in H2

In line but very strong order intake

Signs of momentum picking up

Strong margins, but a small quarter

Swedish Orphan Biovitrum AB: 1 director

A director at Swedish Orphan Biovitrum AB sold 7,723 shares at 288.474SEK and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Little room for errors

Sales pace needs to pick up

Small beat, puts upwards pressure on guidance into H2'25

Raining orders

A solid quarter

If H2 doesn’t step up, '27e won’t stack up

Limited changes post Q1

Consolidated in line weak from JV's

Good Q1e sales, but recent slow-down

Weak Q1, but strong momentum towards 2026

Veidekke (Hold, TP: NOK150.00) - Q1 was a supportive non-event

Q1 EBIT was NOK-43m, slightly below our forecast, with low seasonal profits due to winter effects in the asphalt operations. This is a seasonally insignificant quarter for the company due to the winter season, and, for context, we expect 2025 EBIT of NOK1.7bn. Order intake and backlog were the Q1 strong points. With the results and commentary supportive of our earnings forecasts, we have made minor estimate changes on the group level and reiterate our HOLD, but have cut our target price to NOK15...